Calithera Biosciences (NASDAQ:CALA) Stock Rating Lowered by BidaskClub

Calithera Biosciences (NASDAQ:CALA) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Friday, BidAskClub reports.

CALA has been the topic of a number of other reports. HC Wainwright reissued a “buy” rating and issued a $9.50 target price (up from $7.00) on shares of Calithera Biosciences in a research note on Friday, May 8th. Citigroup increased their target price on shares of Calithera Biosciences from $7.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Zacks Investment Research cut Calithera Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, May 27th. ValuEngine cut shares of Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 2nd. Finally, William Blair reissued a “buy” rating on shares of Calithera Biosciences in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $8.25.

Shares of NASDAQ:CALA opened at $4.70 on Friday. The company has a quick ratio of 8.75, a current ratio of 8.75 and a debt-to-equity ratio of 0.05. Calithera Biosciences has a 1 year low of $2.45 and a 1 year high of $8.18. The business’s 50 day moving average price is $5.22 and its 200-day moving average price is $5.88.

Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.02). As a group, equities research analysts anticipate that Calithera Biosciences will post -1.36 EPS for the current year.

In related news, major shareholder Bvf Partners L. P/Il sold 2,283,598 shares of the firm’s stock in a transaction that occurred on Thursday, May 21st. The shares were sold at an average price of $6.00, for a total transaction of $13,701,588.00. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 11.90% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Assenagon Asset Management S.A. acquired a new position in shares of Calithera Biosciences in the 2nd quarter valued at approximately $1,551,000. Nuveen Asset Management LLC boosted its stake in Calithera Biosciences by 79.2% during the 1st quarter. Nuveen Asset Management LLC now owns 445,428 shares of the biotechnology company’s stock valued at $1,978,000 after purchasing an additional 196,868 shares during the period. State Street Corp grew its stake in shares of Calithera Biosciences by 17.3% in the first quarter. State Street Corp now owns 997,206 shares of the biotechnology company’s stock worth $4,428,000 after purchasing an additional 147,130 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Calithera Biosciences by 21.0% during the first quarter. Geode Capital Management LLC now owns 807,690 shares of the biotechnology company’s stock valued at $3,586,000 after purchasing an additional 140,332 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Calithera Biosciences by 11,376.8% in the first quarter. Russell Investments Group Ltd. now owns 103,291 shares of the biotechnology company’s stock worth $458,000 after purchasing an additional 102,391 shares during the period. Institutional investors own 67.90% of the company’s stock.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Further Reading: What sectors are represented in the FTSE 100 index?

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.